Risk stratification and prognosis after TAVI / Hypertension treatment (drugs and devices) 157rable short term outcomes. On the contrary, a better performance of SAVR compared to transfemoral TAVI for long term mortality and MACCE can be shown, at least when we refere to devices in use until 2012. Objectives: This randomised, multicentre study compared the efficacy of renal denervation (RDN) versus spironolactone addition in patients with true resistant hypertension. We present the 24-month data. Methods: A total of 106 patients with true resistant hypertension were enrolled in this study: 52 patients were randomised to RDN and 54 patients to the spironolactone addition, with baseline systolic blood pressure of 159±17 and 155±17 mmHg and average number of drugs 5.1 and 5.4, respectively. Two-year data are available in 86 patients. Spironolactone addition, as crossover after one year, was performed in 23 patients after RDN, and spironolactone addition followed by RDN was performed in 5 patients. Results: Similar and comparable reduction of 24-hour systolic blood pressure after RDN or spironolactone addition after randomisation was observed, 9.1 mmHg (p=0.001) and 10.9 mmHg (p=0.001), respectively. Similar decrease of office blood pressure was observed, 17.7 mmHg (p<0.001) versus 14.1 mmHg (p<0.001), while the number of antihypertensive drugs did not differ significantly between groups. Crossover analysis showed non-significantly better efficacy of spironolactone addition in 24h systolic and office systolic blood pressure reduction than RDN (3.7 mmHg, p=0.27 and 4.6 mmHg in favour of spironolactone addition, p=0.28, respectively). Meanwhile, the number of antihypertensive drugs was significantly increased after spironolactone addition (+0.7, p=0.001).Changes of systolic blood pressure. Conclusions:In the settings of true resistant hypertension, spironolactone addition (if tolerated) seems to be of better efficacy than RDN in blood pressure reduction over a period of 24 months. However, by contrast to the 12-month results, blood pressure changes are not significantly greater. Introduction: Renal artery stenosis (RAS) is one of the leading causes of severe renal insufficiency, often providing a poor outcome if left untreated. A higher probability of better renal function improvement after revascularization in patients (pts) with severe renal impairment was suggested. Purpose: The present study aim to assess the renal outcome of three categories of patients with significant RAS (>70% unilateral, bilateral and RAS in a solitary kidney) 12 months after stent angioplasty and to identify predictors of predefined renal function improvement for the studied population. Methods: A total of 74 hypertensive pts diagnosed by renal angiography with significant RAS (>70%) were prospectively enrolled, subsequently resulting in 3 groups (34 pts -unilateral RAS, 28 pts -bilateral RAS, 12 pts -RAS in a solitary kidney). Clinical examination, cardiac and renal history, cardiovascular risk factors and comorbidities, laboratory findings ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.